News and comment / Science

From Bench to Bedside in 15 Minutes: A Dangerous Experiment in Comedy

Tim HardmanManaging Director 18 November 2026 7 min read

There are some things in life that are best approached with caution. Nuclear physics, brain surgery, negotiating with your wife and, apparently, attempting to be funny in public. Tomorrow, I shall be attempting all four simultaneously. Well, perhaps not the first three, but certainly the last. My colleague, Dr Stephen Walker, and I have been invited to speak at the London Biotechnology Show in London, where we have been given the rather modest allocation of 15 minutes to cover a subject entitled "From Bench to Bedside: The Story of Developing a New Drug."

For anyone familiar with the drug development process, you will immediately recognise the problem. For those who aren't, let me put it into perspective. When we first started working with Glaxo Wellcome in the 1990s, before it became GSK, this was an introductory training course delivered to new starters over a period of approximately 8 weeks. And that was simply to give them a working understanding of the process.

We have 15 minutes.

I suspect the organisers have either considerable confidence in our abilities or have misunderstood the scale of the undertaking. Either way, we have decided that the only sensible approach is to embrace the absurdity of the task. And, against my better judgement, I have decided to try to make it funny. This is where things become considerably more dangerous.

A history of poor judgement

I should explain that humour is not generally considered one of my more developed professional attributes.

Indeed, various wives over the years have repeatedly told me that I am not funny. I have, for the most part, taken their opinions to heart. Three intelligent women cannot all be wrong, although I suppose there is always the possibility that they have been comparing notes.

To be fair, the available evidence (supporting) is not particularly encouraging. I have a remarkable ability to take even the simplest of jokes and butcher it beyond recognition. What might have been a perfectly acceptable observation in someone else's hands becomes, in mine, an awkward silence punctuated by the sound of people wondering whether I have actually finished speaking.

My one previous attempt to inject humour into a professional presentation remains a particularly painful memory.

Some 30-plus years ago, I was presenting at a meeting of the Society of Hypertension. The audience consisted of a collection of highly respected professors and senior academics, many of whom had spent their careers publishing hundreds of scientific papers.

In a moment of what I can only describe as misplaced confidence, I made a joke suggesting that perhaps some of them had not actually done all the work on those hundreds of publications. I thought it was amusing. They didn't. Not a laugh. Not a chuckle. Not even the reassuring grunt of recognition that occasionally passes for approval at scientific meetings. Nothing. Silence! Awkward! It was one of those moments when you become acutely aware that the next slide cannot come quickly enough.

In retrospect, perhaps I should have considered my audience a little more carefully. There is a difference between making an observation about the realities of scientific publishing and suggesting to a room full of distinguished academics that they might not have been entirely responsible for their own productivity. Even if there was a grain of truth in the observation, it was probably not the best way to win friends and influence people. I should have stuck to the data.

Comedy is a dangerous business

There is, of course, a serious point here. Humour can be a remarkably effective communication tool, but it is also one of the easiest ways to undermine an otherwise perfectly good presentation.

The first consideration is your audience. What works with a room full of colleagues who know you well may be disastrous in front of an audience of strangers. A joke that works at the pub may not work at a scientific conference. And something that seems perfectly reasonable to you may be interpreted rather differently by someone who has spent 30 years developing a particular scientific discipline. Knowing your audience is fundamental.

The second consideration is size. There is something rather forgiving about a small group. You can judge reactions, adjust your delivery and perhaps recover from a slightly unfortunate remark. A large auditorium is rather less accommodating. Once a joke has disappeared into the silence of several hundred people, there is nowhere particularly useful to hide. Silence echoes!

Then there is the subject matter itself. Some topics lend themselves naturally to humour. Others require a little more care. Drug development is actually quite fertile territory. Anyone who has worked in the pharmaceutical industry knows that the journey from an interesting molecule in a laboratory to an approved medicine is full of unexpected obstacles, bureaucratic complexity, scientific uncertainty and the occasional moment of sheer disbelief. There is plenty to laugh about.

The challenge is to ensure that the audience is laughing with you rather than wondering whether you have quite understood the subject. Just rethinking it as I write is making my palms sweat.

And perhaps most importantly, there is the question of delivery. Comedy is a sharp sword. In the hands of a skilled professional, it can be used with extraordinary precision. In the hands of an amateur, it can cause considerable collateral damage. Professional comedians spend years learning timing, pacing, audience engagement and the ability to recognise when something isn't working. They understand that a pause can be more important than the punchline and that sometimes the best joke is the one you decide not to tell. The rest of us tend to assume that because something made us laugh in the shower, it will have the same effect on 200 people in a conference hall. I realise that this is rarely a safe assumption.

From bench to bedside: the impossible presentation

Of course, the underlying challenge remains the subject itself. Developing a new medicine is one of the most complex, expensive and time-consuming undertakings in modern science. It involves basic research, target identification, drug discovery, preclinical studies, toxicology, formulation development, clinical pharmacology, Phase I, II and III clinical trials, regulatory submissions, manufacturing, pharmacovigilance and, eventually, the possibility of making a medicine available to patients. Each of these stages has its own scientific, regulatory and operational challenges – something I hope I know a little about.

There are questions about safety, efficacy, dose, patient selection, manufacturing quality, statistical significance and the interpretation of increasingly complex datasets. There are regulators, ethics committees, investigators, clinical research organisations, medical writers, statisticians and an army of other professionals, all contributing to the process. And somewhere in the middle of all this, someone has to explain what is happening.

Fifteen minutes. Fifteen!

I suspect that even a particularly efficient PowerPoint presentation cannot quite do justice to the subject. Our approach, therefore, has been to acknowledge the ridiculousness of the brief and try to give the audience a flavour of the journey rather than pretend that we can explain every detail. If we can make people smile along the way, so much the better. If we can make them appreciate just how much work goes into bringing a new medicine to patients, even better still. And if we manage to finish within our allotted time, that will be a considerable achievement in itself.

A plea for forgiveness

So, as I prepare for tomorrow, I find myself in the rather unusual position of hoping that my scientific knowledge will be sufficient to compensate for my questionable comedic abilities. I can only hope that my co-presenters are at least moderately funny.

I am also conscious that my three wives, whose collective judgement on my sense of humour has been remarkably consistent, may well be enjoying this particular experiment from a safe distance (though I haven’t spoken to my second wife in nearly 30 years).

I would therefore like to make a small appeal to the readership. Please wish us well. To those attending the London Biotechnology Show, I ask in advance for your patience, goodwill and, above all, forgiveness. Should an ill-advised joke escape my mouth, please remember that it is delivered with the best of intentions, even if the execution leaves something to be desired. And to the fates, the gods of public speaking and whatever other supernatural entities might have influence over proceedings, I ask just one thing: Please ensure that I do not completely wreck my career.

After more than 40 years working in clinical science, drug development and medical communications, it would be a particularly unfortunate way to finish.

Perhaps there is a lesson here. We spend much of our professional lives worrying about scientific accuracy, regulatory compliance, clinical data and the consequences of getting things wrong. Occasionally (I hope), it is worth stepping outside our comfort zones and trying something a little different. Even if that means risking public humiliation.

Tomorrow, we shall attempt to explain the journey from bench to bedside in 15 minutes. Whether we succeed scientifically remains to be seen. Whether I succeed comedically is, frankly, a much bigger gamble. Wish me luck. I think I'm going to need it.

Tim Hardman Written by Tim Hardman · Managing Director Dr Tim Hardman is the Founder and Managing Director of Niche Science & Technology Ltd., the UK-based CRO he established in 1998 to deliver tailored, science-driven support to pharmaceutical and biotech companies. With 25+ years’ experience in clinical research, he has grown Niche from a specialist consultancy into a trusted early-phase development partner, helping both start-ups and established firms navigate complex clinical programmes with agility and confidence. Tim is a prominent leader in the early development community. He serves as Chairman of the Association of Human Pharmacology in the Pharmaceutical Industry (AHPPI), championing best practice and strong industry–regulator dialogue in early-phase research. He ia also a Board member and ex-President of the European Federation for Exploratory Medicines Development (EUFEMED) from 2021 to 2023, promoting collaboration and harmonisation across Europe. A scientist and entrepreneur at heart, Tim is an active commentator on regulatory innovation, AI in clinical research, and strategic outsourcing. He contributes to the Pharmaceutical Contract Management Group (PCMG) committee and holds an honorary fellowship at St George’s Medical School. Throughout his career, Tim has combined scientific rigour with entrepreneurial drive—accelerating the journey from discovery to patient benefit. Follow on LinkedIn ↗

Want the thinking in more depth?

Our free Insider’s Insights guides go further on the topics we write about here.

© 2025 Niche.org.uk     All rights reserved

HomePrivacy policy Corporate Social Responsibility